On 14 April 2026 the Medicines and Healthcare products Regulatory Agency published new guidance on how the amended UK clinical trial legislation aligns with the World Medical Association's Declaration of Helsinki. The guidance is not a change of law — the UK statute, now substantially updated from the 2004 regulations, already forms the primary rulebook — but it resolves a set of practical questions that trial sponsors and investigator teams have been asking for the past year.

For the pharmacy professionals who run investigational medicinal product (IMP) services in hospitals, and the community and primary-care pharmacists who occasionally receive trial patients, the guidance is worth understanding. This piece summarises what is new, what is unchanged and where the friction points sit.

What the Declaration of Helsinki is

The Declaration of Helsinki is the World Medical Association's statement of ethical principles for research involving human subjects. First issued in 1964 and amended multiple times, it sets out requirements on informed consent, protection of vulnerable populations, protocol review, and post-trial access to interventions. It is not itself law in any country but is referenced extensively in national legislation, including in the UK through successive iterations of clinical trial regulation.

The April 2026 MHRA guidance addresses alignment between the declaration's current wording and the amended UK regulations. It does so by making explicit which requirements are satisfied by existing UK statute, which are handled through Good Clinical Practice (GCP), and where conflicts are to be resolved in favour of UK law.

The core rule the guidance sets out

The guidance's headline position: where the Declaration of Helsinki and UK clinical trial regulations conflict, UK law takes precedence. This is not a repudiation of the declaration — the guidance explicitly recommits the UK to Helsinki's ethical principles — but a pragmatic resolution of the handful of places where the two framings diverge. Those include areas such as the exact mechanism of post-trial access, placebo use in certain populations and the definition of "vulnerable" groups.

For investigators, the takeaway is that a protocol that complies with the amended UK regulations and GCP does not need a separate Helsinki-compliance review; the regulatory system has that covered. For sponsors running multi-country trials, the guidance is a reference point when another jurisdiction's ethics committee asks how Helsinki is observed in the UK arm.

What this changes for investigational pharmacy

Hospital pharmacy services that manage IMPs will see three practical effects.

Informed consent documentation. The guidance reaffirms that UK GCP standards for consent meet Helsinki's threshold. Pharmacy teams handling IMP dispensing against a protocol can rely on the consent-documentation process run by the clinical team and do not need to separately verify Helsinki wording in the consent form.

Vulnerable populations. The guidance clarifies that children, pregnant participants, and incapacitated adults remain protected by specific UK regulations (the 2004 instrument as amended) and that pharmacy teams dispensing to these populations should follow the trial-specific Patient Group Direction or Patient Specific Direction without additional Helsinki-layer verification.

Post-trial access. The declaration calls for post-trial access to beneficial interventions where reasonable. UK law does not mandate this in all cases but the guidance encourages sponsors to plan for post-trial access in protocols where it is clinically appropriate. Pharmacy teams may find themselves supporting extended-access arrangements after the main trial closes, including supply logistics and patient counselling.

The companion records-retention guidance

On the same day, MHRA also published updated guidance on archiving and retention of clinical trial records. The two documents are companions. The records-retention piece covers ownership of essential documents, data-integrity expectations, transitional provisions for trials that started under the pre-amendment regime and retention periods that pharmacy teams need to plan against. For trial-running trust pharmacies, the practical question is whether local SOPs need updating to reflect the new retention language; in most cases a review rather than an overhaul is sufficient.

What community pharmacy sees of all this

Most community pharmacists will not directly encounter a trial patient at the counter, but it happens more often than the background rate suggests. A patient participating in an investigator-initiated oncology trial may bring a non-trial prescription to their local pharmacy while on the study. A patient on an ATMP trial may continue routine chronic medication on the high street. Pharmacists should be aware of two points:

• Do not substitute for an IMP. If the patient asks whether their community pharmacist can replace a trial medicine, the answer is always no — the medicine is supplied and accounted for through the trial pharmacy, not through the community route.
• Check for interactions with trial medicines. The patient's trial information sheet usually lists permitted and prohibited concomitant medicines. If a new prescription crosses the counter, the trial team is the right contact for clarity.

These are standard pharmaceutical-care principles. The new MHRA guidance does not change them; it reinforces the regulatory context in which they apply.

Why the guidance matters for the sector

The UK's amended clinical trial regulations are still settling into practical use. Commercial sponsors, academic investigators and NHS trusts are all working through how the new rules interact with existing SOPs, ethics-committee processes and international requirements. By setting out the Helsinki-alignment position clearly, the April 2026 guidance removes a category of ambiguity and lets the sector focus on the more technically demanding parts of the amended regime — simplified application processes, proportionate oversight and transparency requirements.

For pharmacy specifically, the message is continuity. UK GCP, trust SOPs and the 2004-regime-as-amended remain the operative framework. The declaration is a reference point, not a parallel rulebook.

Further reading on PharmSee

• Pharmacy workforce dashboard: /salary
• NHS and investigational pharmacy job market: /app/jobs
• Pharmacy locator: /app/pharmacies

Caveats

This piece summarises the MHRA guidance as published on 14 April 2026. The guidance is not a change in statute; it is an interpretive document. Investigator sites, sponsors and trust pharmacy services should read the full guidance alongside their local SOPs and GCP training. Complex scenarios — particularly in paediatric and capacity-impaired trial populations — should be escalated to the trust R&D team or MHRA directly.

Sources

• MHRA, Declaration of Helsinki and Clinical Trial Regulations alignment, 14 April 2026.
• MHRA, Archiving and retention of clinical trial records, 14 April 2026.
• World Medical Association, Declaration of Helsinki, current revision.